Alterity Therapeutics Limited (ASX:ATH)
Australia · Delayed Price · Currency is AUD | Market Cap | 63.00M -35.6% |
| Revenue (ttm) | 3.61M -33.6% |
| Net Income | -23.40M |
| EPS | -0.11 |
| Shares Out | 229.10M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 538,934 |
| Open | 0.2700 |
| Previous Close | 0.2700 |
| Day's Range | 0.2550 - 0.2850 |
| 52-Week Range | 0.2300 - 0.7850 |
| Beta | -0.02 |
| Analysts | Strong Buy |
| Price Target | 5.52 (+1,906.18%) |
| Est. Earnings | Nov 11, 2026 |
About Alterity Therapeutics
Alterity Therapeutics Limited is engages in research and development of Parkinsonian and neurodegenerative disorders, including Multiple System Atrophy (MSA) and Parkinson’s disease. The company’s lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase II clinical trial for the treatment of Parkinson’s disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; and ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy, as we... [Read more]
Financial Performance
In fiscal year 2026, Alterity Therapeutics's revenue was 3.61 million, a decrease of -33.63% compared to the previous year's 5.44 million. Losses were -23.40 million, 92.6% more than in 2025.
Financial StatementsAnalyst Summary
According to 2 analysts, the average rating for ATH stock is "Strong Buy." The 12-month stock price target is $5.52, which is an increase of 1,906.18% from the latest price.
News
Alterity Therapeutics Limited - Depositary Receipt Price Target Increased by 12.50% to $8.89
The average one-year price target for Alterity Therapeutics Limited - Depositary Receipt (NASDAQCM:ATHE) (DB:PBN0) has been revised to $8.89 / share. This is an increase of 12.50% from the prior estim...
Alterity Therapeutics Releases Appendix 4C – Q1 FY27 Quarterly Cash Flow Report & Corporate Update
Highlights FDA End-of-Phase 2 meeting minutes confirmed the Phase 3 trial design and registrational pathway for ATH434 in Multiple System Atrophy (MSA) New U.S. composition of matter patent granted fo...
Alterity Therapeutics Earnings release: Q1 2027
Alterity Therapeutics released its Q1 2027 earnings on October 29, 2026, summarizing the period's financial results.
Alterity Therapeutics to Present at the Canaccord Genuity Drug and Device Conference
MELBOURNE, Australia and SAN FRANCISCO, Oct. 09, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing ...
Alterity's ATH434 Demonstrates Slower MSA Progression In Phase 2
(RTTNews) - Alterity Therapeutics Ltd. (ATHE) reported new analyses from its Phase 2 ATH434-201 trial showing that ATH434 50 mg slowed functional decline in patients with multiple system atrophy (MSA)...
Alterity Therapeutics Presents New Analyses of ATH434 Phase 2 Data in Multiple System Atrophy at the 2026 International Congress of Parkinson's Disease and Movement Disorders
ATH434 50 mg significantly slowed functional decline in MSA by approximately 52% versus placebo on the 11-item UMSARS at Week 52 with CSF NfL as a covariate
Alterity Therapeutics management to meet virtually with Lake Street
Virtual Meeting to be held on September 21 at 11:30 am hosted by Lake Street.
Alterity Therapeutics management to meet virtually with Lake Street
Virtual Meeting to be held on September 17 at 11 am hosted by Lake Street.
Alterity Therapeutics initiated with a Buy at Lake Street
Lake Street analyst Thomas Flaten initiated coverage of Alterity Therapeutics (ATHE) with a Buy rating and $10 price target The clinical-stage biotechnology company is advancing ATH434 toward a pivota...
Alterity Therapeutics Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference
ATH434 demonstrated significant clinical benefit in early-stage MSA, with FDA-aligned phase III plans targeting a 2–2.5 point treatment difference on UMSARS Part I. Commercial prospects are strong, supported by extended patent protection and active partnering discussions.
Alterity Therapeutics to Participate in a Fireside Chat at the Cantor Global Healthcare Conference 2026
MELBOURNE, Australia and SAN FRANCISCO, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing...
Alterity Therapeutics Annual report: H2 2026
Alterity Therapeutics has published its H2 2026 annual report on August 27, 2026.
Alterity Therapeutics granted new patent for ATH434
Alterity Therapeutics (ATHE) announced that the United States Patent and Trademark Office has granted a new composition of matter patent for ATH434, the company’s lead clinical asset. ATH434 is an…
Alterity Therapeutics Announces Granting of New U.S. Composition of Matter Patent for ATH434
– Newly granted patent extends protection for ATH434 to at least 2045, significantly enhancing its strategic value and long-term commercial potential –
Alterity Therapeutics Transcript: Canaccord Genuity's 46th Annual Growth Conference
ATH434 slowed MSA progression by up to 50% in phase II, with strong efficacy in mobility and swallowing endpoints and a favorable safety profile. Phase III is set for 2024 with FDA alignment, targeting a $2.4 billion market and significant unmet need.
Craig-Hallum bullish on Alterity Therapeutics, initiates with a Buy
As previously reported, Craig-Hallum initiated coverage of Alterity Therapeutics (ATHE) with a Buy rating and $12 price target The firm sees Alterity as a high-risk/high-reward setup around ATH434 in ...
Alterity Therapeutics initiated with a Buy at Craig-Hallum
Craig-Hallum analyst Adam Vogel initiated coverage of Alterity Therapeutics (ATHE) with a Buy rating and $12 price target
Alterity Therapeutics to Present at the 46th Annual Canaccord Genuity Growth Conference
MELBOURNE, Australia and SAN FRANCISCO, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing ...
Alterity Therapeutics Releases Appendix 4C – Q4 FY26 Quarterly Cash Flow Report & Corporate Update
Highlights FDA End-of-Phase 2 (EOP2) meeting minutes confirmed a registrational pathway for ATH434 in Multiple System Atrophy (MSA) FDA agreed that a single pivotal Phase 3 trial plus confirmatory evi...
Alterity Therapeutics Earnings release: Q4 2026
Alterity Therapeutics released its Q4 2026 earnings on July 29, 2026, summarizing the period's financial results.
Alterity Therapeutics to Participate in the Virtual BTIG Biotechnology Conference 2026
MELBOURNE, Australia and SAN FRANCISCO, July 21, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing ...
Alterity Therapeutics receives FDA meeting minutes on pathway for ATH434
Alterity Therapeutics (ATHE) announced that it has received the official meeting minutes from its End-of Phase-2 meeting for ATH434 in Multiple System Atrophy from the FDA. The minutes confirm the…
Alterity Therapeutics Receives FDA End-of-Phase 2 Meeting Minutes Confirming Registrational Pathway for ATH434 in Multiple System Atrophy
– Official FDA minutes confirm the previously announced End-of-Phase 2 meeting outcomes and provide additional detail on the planned Phase 3 protocol —
Alterity Therapeutics initiated with a Buy at JonesResearch
JonesResearch initiated coverage of Alterity Therapeutics (ATHE) with a Buy rating and $16 price target Alterity’s oral iron chaperone, ATH434, is set to enter Phase 3 development for multiple system…
Alterity Therapeutics assumed with a Buy at Ladenburg
Ladenburg analyst Caroline Palomeque assumed coverage of Alterity Therapeutics (ATHE) with a Buy rating and $10 price target Alterity is entering late-stage clinical development which “is an ideal tim...